Side-by-side · Research reference
KPVvsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED13/39 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
KPV
PNC-27
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
No melanocortin receptor binding
N/A — cytotoxic mechanism, not signaling modulation
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
PNC-27
Frequency
Daily or 2–3× per week
—
Lower / starter dose
100 mcg / day
—
Duration
4–8 weeks per cycle
—
Reconstitution
Bacteriostatic water (SQ form)
—
Timing
No specific time; often taken with / before meals (oral)
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
03Metabolic / Fat Loss Evidence
Parameter
KPV
PNC-27
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
KPV
PNC-27
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
—
Human safety data
—
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
PNC-27
—05Administration Protocol
Parameter
KPV
PNC-27
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Timing
Morning preferred; oral form taken with / before meals.
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.
5. Needle
29–31G insulin syringe (SQ form).
—
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
PNC-27
— no documented stacks